{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:50:21Z","timestamp":1777297821907,"version":"3.51.4"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Oral Diseases"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Post\u2010marketing pharmacosurveillance is important to reduce harm to patients from marketed drugs. Oral adverse drug reactions (OADRs) are seldom reported and only few OADRs are listed scarcely in summary of product characteristics (SmPC) of drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Structured search for OADRs in the Danish Medicines Agencies database from January 2009 to July 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty\u2010eight percent of OADRs were categorized as \u201cserious\u201d where oro\u2010facial swelling was reported 1041 times, medication\u2010related osteonecrosis of the jaw (MRONJ) 607 times and para\u2010 or hypoaesthesia 329 times. Four\u2010hundred\u2010eighty OADRs in 343 cases were related to biologic or biosimilar drugs where 73% affected the jawbone as MRONJ. Physician reported 44%, dentists 19% and citizens 10% of OADRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Health care professionals had a sporadic reporting pattern that seemed to be influenced by the debate in the community and in professional circles but also by the information in the SmPC of the drugs. The results indicate some reporting stimulation of OADRs in relation to Gardasil 4, Septanest, Eltroxin and MRONJ. Eventually the knowledge of OADRs increases but there is a risk of skewed information if reporting is not systematic, reliable and consistent. All healthcare professionals must be educated in spotting and reporting all suspected adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/odi.14559","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:28:30Z","timestamp":1678408110000},"page":"1573-1582","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Danish post\u2010marketing pharmacosurveillance of spontaneous Oral Adverse Drug Reactions 2009\u20132019"],"prefix":"10.1111","volume":"30","author":[{"given":"Birita Sofia","family":"Ellefsen","sequence":"first","affiliation":[{"name":"Section of Oral Pathology and Medicine, Department of Odontology, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4693-0433","authenticated-orcid":false,"given":"Kristine R\u00f8n","family":"Larsen","sequence":"additional","affiliation":[{"name":"Section of Oral Pathology and Medicine, Department of Odontology, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Reibel","sequence":"additional","affiliation":[{"name":"Section of Oral Pathology and Medicine, Department of Odontology, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Kragelund","sequence":"additional","affiliation":[{"name":"Section of Oral Pathology and Medicine, Department of Odontology, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009069.pub3"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010018\u20100588\u20105"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpe.12685"},{"key":"e_1_2_10_5_1","first-page":"834","article-title":"Articain \u2013 fortsat fokus p\u00e5 forebyggelse og korrekt anvendelse","volume":"116","author":"Danish Health Authority","year":"2012","journal-title":"Danish Dental Journal"},{"key":"e_1_2_10_6_1","unstructured":"Danish Medicines Agency. (2014).ADRs related to thyroid hormone replacement therapy: Remember the clinical picture at dose optimisation. Danish Pharmacovigilance Update."},{"key":"e_1_2_10_7_1","unstructured":"Danish Medicines Agency. (2019a).The Danish medicines Agency's pharmacovigilance strategy. Copenhagen: 1\u201310."},{"key":"e_1_2_10_8_1","unstructured":"Danish Medicines Agency(2019b).https:\/\/laegemiddelstyrelsen.dk\/da\/bivirkninger\/biologiske\u2010og\u2010biosimilaere\u2010laegemidler\/liste\u2010over\u2010udvalgte\u2010biologiske\u2010laegemidler\/"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010017\u20100575\u20105"},{"key":"e_1_2_10_10_1","unstructured":"European Medicines Agency. (2015).Review concludes evidence does not support that HPV vaccines cause CRPS or POTS.https:\/\/www.ema.europa.eu\/en\/documents\/press\u2010release\/review\u2010concludes\u2010evidence\u2010does\u2010not\u2010support\u2010hpv\u2010vaccines\u2010cause\u2010crps\u2010pots_en.pdf"},{"key":"e_1_2_10_11_1","unstructured":"European Medicines Agency. (2020).List of medicinal products under additional monitoring.https:\/\/www.ema.europa.eu\/en\/documents\/additional\u2010monitoring\/list\u2010medicinal\u2010products\u2010under\u2010additional\u2010monitoring_en\u20100.pdf"},{"key":"e_1_2_10_12_1","volume-title":"Directive 2001\/83\/EC of the European Parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use","author":"European Union","year":"2001"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2010.0281"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2018.08.015"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2011.0223"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.018"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7645465"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.03.028"},{"key":"e_1_2_10_19_1","volume-title":"Baggrundsnotat om unders\u00f8gelse af risiko for nerveskader","author":"Lexner M. O.","year":"2013"},{"key":"e_1_2_10_20_1","unstructured":"Medical Dictionary for Regulatory Activities. (n.d.).MedDRA Hierarchy.https:\/\/www.meddra.org\/how\u2010to\u2010use\/basics\/hierarchy"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2018.03.008"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200730100\u201000007"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/joor.12664"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13160"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bdj.2019.98"},{"key":"e_1_2_10_26_1","unstructured":"The Danish Association of the Pharmaceutical Industry. (2019).The Danish Association of the Pharmaceutical Industry (Lif).https:\/\/pro.medicin.dk\/specielleemner\/emner\/318675"},{"key":"e_1_2_10_27_1","unstructured":"The Danish Ministry of Health. (2015).Bekendtg\u00f8relse om indberetning af bivirkninger ved l\u00e6gemidler m.m. Copenhagen BEK nr 1823 af 15\/12\/2015."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268\u2010016\u20100153\u20109"},{"key":"e_1_2_10_29_1","first-page":"1","volume-title":"Quality assurance and safety of medicines team. Safety of medicines: A guide to detecting and reporting adverse drug reactions: Why health professionals need to take action","author":"World Health Organization","year":"2002"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bdj.2013.426"}],"container-title":["Oral Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/odi.14559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/odi.14559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T08:42:45Z","timestamp":1721896965000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/odi.14559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/odi.14559"],"URL":"https:\/\/doi.org\/10.1111\/odi.14559","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/ODI.14559\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.14559\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.14559\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.14559\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.14559\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.14559\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1354-523X","1601-0825"],"issn-type":[{"value":"1354-523X","type":"print"},{"value":"1601-0825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"2022-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}